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The arachidonic acid metabolites, collectively referred to as
eicosanoids, and nitric oxide (NO) originating from the amino
acid L-arginine following activation of nitric oxide synthase
(NOS), have recently become the focus of intense investigation
insofar as the biology of glomerulonepritis is concerned. Three
key reasons are: (a) it was realized that certain eicosanoids (those
of the arachidonate cyclooxygenase pathway) and NO can be
synthesized in a constitutive or inducible manner; (b) while their
constitutive release plays a homeostatic role in the kidney, their
inducible synthesis can promote cell injury; and (c) regulatory
interactions may occur between NO and certain eicosanoids and
result in amplification of injury. A number of recent reviews have
dealt with the synthesis and origin of eicosanoids and of NO in the
normal and diseased kidney [1, 2]. This review emphasizes
regulatory interactions that may occur between eicosanoids and
NO in glomerulonephritis, and addresses issues regarding the
cytotoxic potential of such interactions.
PRESENCE AND PHYSIOLOGIC ROLE OF THE
L-ARGININE:NITRIC OXIDE PATHWAY IN THE KIDNEY
Whereas the role of eicosanoids in renal physiology and pathol-
ogy has been extensively explored in the last decade, the presence
and significance of the L-arginine:NO pathway in the kidney has
only recently become apparent. Nitric oxide is a reactive radical
gas formed from the terminal guanidino nitrogen atom of the
amino acid L-arginine. This reaction is catalyzed by the enzyme
nitric oxide synthase (NOS). At least three NOS enzymes have
been described. The endothelial and neuronal isoforms are con-
stitutively expressed and are quiescent until activated by increased
Ca21 levels in a calmodulin-dependent manner. The inducible
NOS (iNOS) is expressed following transcriptional activation by
cytokines or lipopolysaccarides (LPS) [3]. Following its induction,
iNOS remains active for sustained periods in a Ca21-independent
manner. Production of NO from the constitutive forms of NOS is
short-lived and regulates a number of homeostatic functions
including modulation of renovascular tone, renin secretion, the
tubuloglomerular feedback response, and sodium excretion [1, 4].
The topography of NOS synthase isoforms in the nephron has
recently become ellucidated. Terada et al demonstrated the
presence of constitutive NOS in the glomerulus where they also
found abundant expression of soluble guanylate cyclase, the well
established acceptor of NO [5]. Mohaupt and co-investigators
have recently reported the expression and induction of mRNAs
encoding two inducible nitric oxide synthases in the rat nephron
and found that endotoxemia and cytokines differentially induce
their expression [6]. Nitric oxide originating from constitutive
NOS plays an important homeostatic role in the glomerular
microcirculation. Thus, inhibition of NOS in the normal rat results
in glomerular arteriolar vasoconstriction and glomerular hypoper-
fusion. Efferent arteriolar resistance is disproportionately in-
creased resulting in glomerular capillary hypertension. In addi-
tion, the glomerular capillary ultrafiltration coefficient, Kf, drops
[7]. These observations have established NO as a basal tonic
dilator of the glomerular microcirculation. This effect is further
supported by the observation that cultured glomerular endothelial
cells release NO [8].
COACTIVATION OF THE ARACHIDONIC ACID AND THE
L-ARGININE:NITRIC OXIDE PATHWAYS IN
GLOMERULONEPHRITIS
Using experimental models of glomerulonephritis investigators
have characterized conversion of arachidonic acid to various
eicosanoids via the cyclooxygenase and lipoxygenase pathways,
and generation of nitric oxide from L-arginine via nitric oxide
synthase.
In models of glomerulonephritis induced by antibody against
the glomerular basement membrane, the glomerular epithelial
cell and the glomerular mesangial cell, it was demonstrated that
the synthesis of arachidonate cyclooxygenation and lipoxygen-
ation eicosanoids in isolated glomeruli is enhanced [9]. The most
abundant arachidonate cyclooxygenation eicosanoids are the
prostaglandins (PG)E2 and PGF2a, and thromboxane (Tx)A2 [10].
The most abundant arachidonate lipoxygenation eicosanoids are
leukotriene (LT)B4 and 5- and 12-hydroxyeicosatetraenoic acid
(HETE) [11]. In the same models of injury it was demonstrated
that generation of nitric oxide from L-arginine in isolated glomer-
uli is also increased [12]. The temporal relationship between
glomerular eicosanoid synthesis and NO generation in the course
of glomerular injury induced by anti-GBM antibody is diagramati-
cally shown in Figure 1. In the same figure, changes in glomerular
filtration rate (GFR), infiltration of glomeruli by platelets and
leukocytes, and proliferation and accumulation of extracellular
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matrix are also shown. The following points are emphasized: (a)
Enhanced glomerular synthesis of both eicosanoids and NO
occurs and peaks at very early stages of the immune injury (within
the first 24 hr). (b) The peak of eicosanoid synthesis coincides with
a marked drop in GFR. Glomerular filtration rate subsequently
recovers partially despite continued synthesis of vasoconstrictor
eicosanoids (TxA2). This recovery is coincidental with peak
generation of NO. (c) At stages of glomerulonephritis beyond the
early phase (24 hr), a dichotomy in glomerular eicosanoid synthe-
sis occurs; whereas synthesis of PGs, TxA2 and 12-HETE remains
enhanced, and that of arachidonate 5-lipoxygenation eicosanoids
(5-HETE and LTB4) becomes impaired. Following its peak,
glomerular generation of NO is sustained and parallels that of
TxA2 and 12-HETE.
In glomerulonephritis, eicosanoids and NO may originate ei-
ther from intrinsic glomerular cells or from infiltrating platelets
and leukocytes. Using platelet depletion and leukocyte depletion
studies, it was shown that activated infiltrating macrophages
account to a large extent for the glomerular origin of 5-HETE and
LTB4, whereas infiltrating platelets entirely account for the origin
of 12-HETE and to a lesser extent for that of TxA2 [13]. Using the
same approach it was shown that infiltrating macrophages are the
source of NO in glomeruli isolated from rats with experimental
membranous nephropathy [14] and mesangioproliferative ne-
phropathy [15]. Thus, the infiltrating activated macrophage has
been identified as a key site where synthesis of both eicosanoids
and NO occurs in glomerulonephritis. However, a possible con-
tribution of mesangial cells should not be ignored [16].
An important aspect of the arachidonic acid and of the L-
arginine:NO pathways is that cyclooxygenation of arachidonic
acid to prostaglandins or conversion of L-arginine to NO may
occur either by constitutive or by inducible isoforms of cyclooxy-
genase (COX) or nitric oxide synthase (NOS), respectively. This is
of major importance in the biology of glomerulonephritis because
activation of the inducible isoforms of these enzymes can result in
sustained synthesis of proinflammatory prostaglandins and in
sustained high-output generation of NO. Macrophages infiltrating
glomeruli in the course of glomerulonephritis are likely to express
inducible COX and NOS as a result of their activation by
proinflammatory cytokines following adherence to the glomerular
capillary endothelium. Indeed, in forms of experimental glomer-
ulonephritis in which glomerular infiltration by macrophages is a
prominent feature, iNOS was immunocytochemically localized in
these cells [17]. In the same forms, enhanced expression of
inducible cyclooxygenase [also referred to as COX-II or prosta-
glandin H synthase (PGHS-II) ] was also demonstrated [18].
Cytooxygenase (COX)-II expression has not only been detected in
isolated glomeruli but also in mesangial cells after exposure to
cytokines [19–21].
PUTATIVE INTERACTIONS BETWEEN THE
ARACHIDONIC ACID AND THE L-ARGININE:NITRIC
OXIDE PATHWAYS
In its capacity as a reactive radical gas, NO binds avidly to iron
and iron-containing enzymes. A multitude of effects mediated by
NO have been attributed to its high affinity for iron-containing
substrates. For example, the ability of NO to inhibit platelet
aggregation and to relax vascular smooth muscle has been attrib-
uted to NO binding to the heme-Fe11 of the soluble guanylate
cyclase leading to stimulation of this enzyme and subsequent
increase in the levels of cGMP [22]. Similarly, NO interacts with
hemoglobin and with iron-sulfur centers in key enzymes of the
respiratory cycle and DNA synthesis [23]. Arachidonate cycloox-
ygenase may become a target for NO because it contains an
iron-heme center at the site that confirms its hydroperoxidase
function [24]. Binding of NO to this center may enhance cycloox-
ygenase activity. Evidence that this may indeed occur has emerged
recently. The initial observations pointing to up-regulation of
Fig. 1. Time course of synthesis of eicosanoids
and generation of nitric oxide (NO) in
glomeruli isolated following immune injury
induced by anti-glomerular basement
membrane (GBM) antibody in the rat. Shown
in parallel are changes in GFR and in
glomerular histopathology (influx of platelets
and macrophages, proliferation and
accumulation of extracellular matrix). Patterns
of eicosanoid synthesis and of NO generation
are presented diagramatically and are based on
observations reported in references 10 to 16.
Enhanced eicosanoid synthesis peaks when
GFR falls. While synthesis of prostaglandins
(PG’s), thromboxane (Tx)A2 and 12-
hydroxyeicosatetraenoic acid (HETE) is
sustained in the course of immune injury, that
of 5-HETE and LTB4 is short-lived and
becomes impaired at early stages of injury.
GFR subsequently recovers despite sustained
production of vasoconstrictor eicosanoids
(TxA2). The recovery in GFR coincides with
peak generation followed by sustained release
of NO.
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cyclooxygenase activity by NO were based on macrophages stim-
ulated with endotoxin. In these cells, endotoxin stimulated iNOS
as well as the inducible isoform of cyclooxygenase (COX-II)
resulting in large production of NO and of prostaglandins,
respectively. Pharmacologic inhibition of iNOS not only reduced
the release of NO but also that of prostaglandins [25]. In these
studies the iNOS inhibitors employed were specific in that they
did not have an effect on COX activity, nor did they alter the level
of induction of COX-II. To further explore the role of NO in
up-regulating COX-II activity, interleukin (IL-1B) stimulated
human fibroblast cells that did not possess an endogenous L-
arginine:NO pathway were exposed to exogenous NO. Exposure
of IL-1B stimulated fibroblasts to either NO or to two NO donors,
sodium nitroprusside and glyceryltrinitrite, increased COX activ-
ity by at least fourfold and production of prostaglandins [25]. This
was independent of an effect of NO on the soluble guanylate
cyclase. A likely mechanism by which NO activates COX is direct
stimulation of the enzyme. Indeed, NO directly increases COX
activity of microsomal sheep seminal vessels as well as the activity
of murine recombinant COX-I and COX-II [25]. The exact
molecular mechanism by which NO activates COX remains to be
identified. In addition to binding to the heme-iron center of COX,
NO interacts with oxygen-derived free radicals such as the super-
oxide ion (O2
2), which is also released at sites of inflammatory
injury. Interaction between NO and O2
2 leads to the formation of
peroxynitrite (ONOO2), which can then decompose to form the
hydroxyl radical, OHz. Thus, NO may augment COX activity by
acting as an anti-oxidant (removal of O2
2) or by generating
ONOO2 and OHz that can subsequently activate COX. Indeed, it
was shown that O2
2 and OHz can modulate the COX pathway
[26]. Finally, it was recently shown that NO nitrosylates cystein
residues in the catalytic domain of COX enzymes [27]. This points
to an additional/alternative mechanism whereby NO can stimulate
COX.
In vivo studies supporting regulatory interactions between the
arachidonic acid and the L-arginine:NO pathways are also emerg-
ing. In endotoxin-induced septic shock in rats, inhibition of NOS
using aminoguanidine reduces the release of prostacycline (PGI2)
by approximately 85% in plasma and urine [28]. Rat islet cells or
vascular smooth muscle cells stimulated with IL-1B release NO
and prostaglandins; inhibition of NO production blocks PGE2
release [29, 30]. In bovine coronary microvascular endothelial
cells NO activates constitutive cyclooxygenase leading to in-
creased production of prostacyclin [31]. In a rat model of exper-
imental glomerulonephritis resembling human forms of rapidly
progressive crescentic nephritis, iNOS inhibition using a relatively
selective pharmacologic inhibitor results in reduced synthesis of
the arachidonate cyclooxygenation products, PGE2 and PGI2, in
isolated glomeruli without an effect on TxA2 [this issue, 65].
Arachidonate lipoxygenases may also become NO targets be-
cause they contain non-heme iron [32]. Indeed, bond formation
between NO and the non-heme iron of lipoxygenase was demon-
strated using purified soybean 15-lipoxygenase and methods of
electron spin resonance spectroscopy [33]. Whether this binding
results in up- or down-regulation of lipoxygenase activity is of
apparent importance in forms of glomerulonephritis character-
ized by enhanced arachidonate lipoxygenation to hydroxyeicosa-
tetraenoic acids (HETE) and leukotrienes and enhanced genera-
tion of iNOS-derived NO. Indeed, in experimental rapidly
progressive nephritis, pharmacologic inhibition of iNOS results in
reduced synthesis of 5-HETE and 15-HETE and of LTB4 [65].
Evidence that eicosanoids may regulate generation of NO is
also emerging. Arachidonic acid and the leukotrienes (LTB4)
stimulate generation of NO in neutrophils and platelets in
amounts sufficient to inhibit platelet aggregation [34]. On the
other hand, eicosanoids can modulate NOS expression. In this
regard, PGE2 negatively modulates iNOS induction in glomerular
mesangial cells in response to interleukin-1 [35]. In experimental
rapidly progressive glomerulonephritis inhibition of cyclooxygen-
ase or of 5-lipoxygenase enhance expression of iNOS in isolated
glomeruli [65].
It becomes clear from the evidence reviewed above that regu-
latory interactions between arachidonate cyclooxygenation or
lipoxygenation pathways and the L-arginine:NO pathway may
develop in the glomerular milieu in the course of glomerulone-
phritis. Such interactions may potentiate adverse hemodynamic
and cytotoxic effects thereby amplifying the extent of renal
hemodynamic impairment and glomerular cell injury. For exam-
ple, NO-driven stimulation of proinflammatory eicosanoids (TxA2
and leukotrienes) would promote platelet aggregation (TxA2),
leukocyte adhesion to the glomerular capillary endothelium via
increased expression of adhesion molecules (TxA2 and leukotri-
enes), and constriction of the glomerular arterioles (TxA2, LTD4).
On the other hand, regulation of iNOS by eicosanoids would
modulate NO generation. A diagrammatic presentation of inter-
actions that may occur between the arachidonate cyclooxygenase
and lipoxygenase pathways and the L-arginine:NO pathway is
shown in Figure 2.
RENAL HEMODYNAMIC EFFECTS OF EICOSANOIDS AND
NITRIC OXIDE IN GLOMERULONEPHRITIS
Eicosanoids and nitric oxide synthesized and released in the
glomerular milieu in the course of glomerulonephritis may have
opposing or additive effects on the glomerular microvasculature.
NO, PGE2 and PGI2 preserve GFR and renal blood flow (RBF)
in experimental models of glomerulonephritis via a dilatory effect
on the renal vasculature. This was shown in studies assessing the
impact of cyclooxygenase (COX) or nitric oxide synthase (NOS)
inhibition on changes in GFR and RBF. Cyclooxygenase (COX)
inhibition using non-steroidal anti-inflammatory drugs (NSAIDs)
reduces glomerular synthesis of PGE2 and PGI2 and markedly
decreases GFR and RBF in anti-GBM antibody-induced glomer-
ulonephritis in the rat [36]. In the same model, NOS inhibition
using systemic administration of the L-arginine analog SG-mono-
methyl-L-arginine results in reduced glomerular plasma flow rate,
a drop in the glomerular capillary ultrafiltration coefficient, Kf,
and an increase in efferent arteriolar constriction resulting in
intraglomerular capillary hypertension and exacerbation of pro-
teinuria [37]. These adverse effects may occur due to an unop-
posed effect of vasoconstrictors by NO as a result of inhibition of
renal NO synthesis. Established vasoconstrictors include the
eicosanoids thromboxane A2 and LTD4. In anti-GBM or anti-Thy
1 antibody mediated glomerulonephritis, these two eicosanoids
mediate the decrease in GFR by increasing the afferent arteriolar
resistance and decreasing the glomerular capillary ultrafiltration
coefficient [38, 39]. The changes in GFR that occur following
anti-GBM antibody-induced glomerulonephritis are shown in
Figure 1. The marked decrement in GFR immediately following
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onset of injury (1 hr) is mediated by TxA2 and LTD4 [38, 39].
Glomerular filtration rate subsequently recovers despite sustained
increments in the vasoconstrictor TxA2, indicating that the vaso-
constrictor effect of this eicosanoid is opposed. Potential opposing
factors are vasodilatory prostaglandins (PGE2 and PGI2) the
glomerular synthesis of which is also enhanced at this stage of the
immune injury [10], and NO the generation of which peaks at the
point of recovery in GFR (Fig. 1) [12]. In other forms of
glomerular immune injury, such as the one induced by anti-Thy 1
antibody, enhanced glomerular synthesis of TxA2 also occurs but
is not accompanied by increased generation of the vasodilatory
prostaglandins PGE2 and PGI2 [13]. Yet, GFR still recovers
despite marked increases in glomerular TxA2 levels. This obser-
vation questions the role of vasodilatory prostaglandins in oppos-
ing the vasoconstrictor effect of TxA2 on the glomerular micro-
vasculature following immune injury and points to NO as the
likely vasodilator that may oppose the effect of TxA2. However,
direct evidence for such opposing interaction between TxA2 and
NO at the level of the glomerular microvasulature is lacking.
EICOSANOIDS AND NITRIC OXIDE AS MEDIATORS OF
CYTOTOXICITY IN GLOMERULONEPHRITIS
A sustained synthesis of arachidonate cyclooxygenation prod-
ucts (PGs and TxA2) and a sustained generation of NO occur in
the course of glomerular immune injury (Fig. 1). This is likely due
to activation of the inducible form of cyclooxygenase (COX-II)
and of the inducible isoform of nitric oxide synthase (iNOS) [16,
17].
Cyclooxygenase (COX) catalyzes the committed step in pros-
taglandin biosynthesis from arachidonic acid, specifically the
oxygenation of arachidonic acid to PGG2 and reduction of PGG2
to PGH2. It has recently become apparent that there are two
different isoforms of COX, referred to as COX-I and COX-II,
and encoded by separate genes [40]. Both COX-I and COX-II
probably catalyze reactions that are mechanistically identical and
the two enzymes exhibit the same Km values for their substrate,
arachidonic acid. The biological basis for the existence of two
distinct cyclooxygenases is not well understood; COX-I is consti-
tutively expressed in most tissues and is believed to mediate
“housekeeping” functions. Surprisingly, however, COX-I deficient
mice are generally healthy and develop normally. Their kidneys
show minimal abnormalities, mainly scarce foci of immature
tubules [41]. In contrast, COX-2 deficient mice die early (by eight
weeks). Pathologically, their tissues are normal except for kidney
tissue, the maturation of which stops early after only a small
number of nephrons have developed. The majority of glomeruli
and tubules are immature while the residual nephrons develop
glomerular sclerosis, interstitial inflammation and progression to
end stage disease [42]. Different patterns of expression of COX-I
and COX-II have been identified in the kidney, that is, COX-I is
mainly expressed in the collecting tubule while COX-II in the
macula densa [43].
The most dramatic difference between the two COX isoen-
zymes relates to regulation of their expression. While expression
of COX-I is maintained at constant levels, that of COX-II can be
dramatically increased during inflammation [44], an observation
that has led to the proposal that activation of COX-II results in
generation of proinflammatory prostaglandins. The induction of
COX-II by proinflammatory cytokines and during inflammatory
responses in cells that mediate inflammation, that is, the macro-
phage, and the reduced expression of this enzyme by anti-
inflammatory agents such as corticosteroids, provides circumstan-
tial evidence to support this role.
It was originally presumed that COX-I is the site of action of
non-steroidal anti-inflammatory drugs (NSAIDS). However, the
discovery of the COX-II isoenzyme and its association with
inflammation has suggested that the therapeutic target of
NSAIDS functioning in their anti-inflammatory capacity is COX-
II. This observation has advanced the attractive concept that use
of non-steroidal anti-inflammatory agents that can selectively
Fig. 2. Potential interactions between the arachidonic acid and the L-arginine:nitric oxide (NO) pathways in glomerular immune injury. Following
injury, macrophages infiltrating glomeruli are activated and generate, (1) prostaglandins (PGs), thromboxane (Tx)A2 and leukotrienes (LTs) from
arachidonic acid via cyclooxygenase and lipoxygenases; and (2) nitric oxide from L-arginine via inducible nitric oxide synthase (iNOS). A positive
regulatory effect of nitric oxide on arachidonate cyclooxygenase is well established (1). Evidence for a positive regulatory effect of nitric oxide on
lipoxygenases is also emerging. Evidence also points to a downregulatory effect of prostaglandins and leukotrienes on expression of iNOS. Solid arrows
indicate definitive evidence. Broken arrows indicate emerging evidence.
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inhibit COX-II would result in a beneficial anti-inflammatory
effect without the adverse consequences of COX-I inhibition,
such as peptic ulcer formation and renal functional impairment
(decreased RBF and GFR). This attractive concept has not yet
been tested in inflammatory processes involving the kidney, such
as glomerulonephritis. Preliminary evidence does indicate that in
experimental glomerulonephritis there is up-regulation of glomer-
ular COX-II expression [17]. Whether this promotes glomerular
inflammatory injury is unknown. For example, in mice lacking
COX-II, the severity of inflammatory responses to tetradecanoyl
phorbol acetate or to arachidonic acid is not diminished in a
model of acetone-induced ear inflammation [42].
As mentioned earlier, NO can up-regulate the activity of both
COX-I and COX-II. It is, therefore, quite possible that in the
course of glomerular immune injury the sustained high-output
generation of NO originating from activation of iNOS can “drive”
synthesis of proinflammatory prostaglandins and TxA2 by simu-
lating COX-II. This could amplify the inflammatory injury to
intrinsic glomerular cells. Whether sustained generation of proin-
flammatory eicosanoids in the glomerular milieu in the course of
glomerulonephritis is injurious to glomerular cells is debatable.
Solid evidence that proinflammatory eicosanoids including PGs,
TxA2, and the leukotrienes can directly effect cell injury is lacking.
Indeed, in other inflammatory conditions such as osteoarthritis,
inhibition of cyclooxygenase using NSAIDS reduces synthesis of
PGs and TxA2 and alleviates symptoms. Yet, the destruction of
joints by the inflammatory process is not prevented. In contrast,
iNOS-derived NO can directly effect cell injury. This can occur
either directly by NO itself or by oxidation products of NO.
Examples of direct toxic effects mediated by NO itself include: (a)
inhibition of cytochrome P450 [45]; (b) reversible inhibition of
ribonucleotide reductase, which is a critical enzyme for synthesis
of DNA precursors [46]; and (c) irreversible inhibition of cyto-
chrome C oxidase, which may promote leakage of superoxide
from the mitochondrial electron transport chain [47].
A key mechanism of injury attributed to production of nitric
oxide is its reaction with superoxide (O2
2) to form peroxynitrite
(ONOO2). Peroxynitrite is not a free radical and its formation is
irreversible. In infiltrative forms of glomerulonephritis, both NO
and superoxide can be released in the glomerular milieu from
infiltrating leukocytes. Therefore, formation of peroxynitrite is
likely to occur. However, the concentration of superoxide is
generally kept low by its scavenger superoxide dismutase the
intracellular concentration of which is quite high (estimated 4 to
10 mM in brain and liver). Thus, very high concentrations (mM
levels) of NO must be attained in order for NO to effectively
compete with superoxide dismutase and react with superoxide to
form peroxynitrite. This may only occur following activation of the
inducible NOS, which, as reviewed above, results in sustained
high-output generation of NO. Whether peroxynitrite is indeed
generated in the glomerular milieu in the course of glomerulone-
phritis is unknown. One indirect approach to detect its formation
is to search for an in vivo “fingerprint” of interaction between
peroxynitrite and protein tyrosine residues. Nitration of protein
tyrosine residues occurs following formation of peroxynitrite and
its subsequent cleavage to produce hydroxyl anion and nitronium
ion (NO2
1). This cleavage is catalyzed by transition metals
including metal centers of superoxide dismutase and myeloperox-
idase [48]. The nitronium ion formed in this manner can nitrate
protein tyrosine residues to form 3-nitrotyrosine which is regarded
as the fingerprint of peroxynitrite in vivo. Detection of nitroty-
rosine-containing proteins has recently become possible using
antibodies against these proteins. Using these antibodies, it was
demonstrated that extensive nitration of protein tyrosine residues
occurs in human atherosclerotic lesions [49].
Once formed as a result of the reaction between NO and
superoxide, peroxynitrite can be particularly toxic. Thus, protona-
tion of peroxynitrite results in its isomerization to peroxynitrous
acid. This can subsequently yield hydroxyl radical and nitrogen
dioxide. In addition to generating these two toxic radicals, per-
oxynitrous acid can itself oxidize iron/sulfur centers, zinc fingers
and protein thiols. Examples of peroxynitrite-induced cytotoxicity
include: (a) inactivation of a-1-anti-protease inhibitor [50], which
is a protease inhibitor that plays an important protective role in
the lung against neutrophile-derived proteases; (b) damage of
amiloride-sodium sensitive channels [51]; (c) mitochondrial injury
the extent of which is more severe than that induced by NO [52];
and (d) oxidation of low density lipoproteins to a form that
facilitates their uptake by activated macrophages [53].
IS INHIBITION OF NITRIC OXIDE A REASONABLE GOAL
IN GLOMERULONEPHRITIS?
As reviewed above, generation of NO in the course of glomer-
ulonephritis is important in preserving GFR. Yet, NO is most
likely derived from activation of iNOS [14, 15]. Therefore, its
generation can be sustained and of high output and can cause cell
injury by the mechanisms reviewed above. A critical dilemma thus
emerges: should generation of NO (particularly of iNOS-derived
NO) be left unopposed to preserve GFR or should it be inhibited
in order to protect glomerular cells from oxidative injury at the
risk of causing renal vasoconstriction and intraglomerular or
systemic hypertension? An additional risk of inhibiting glomerular
generation of NO in infiltrative forms of glomerulonephritis is
that this maneuver may enhance platelet and leukocyte adherence
to the glomerular capillary endothelium thereby promoting plate-
let and leukocyte-induced injury. A number of recent studies
support both the argument of leaving NO generation unopposed
and that of inhibiting NO generation. In anti-GBM antibody-
induced glomerulonephritis, inhibition of NO synthesis using
systemic administration of nonselective NOS inhibitors or sys-
temic NOS substrate (L-arginine) depletion, results in intraglo-
merular hypertension [37] and worsening of proteinuria [37, 54].
Contrasting these findings are those in murine lupus nephritis in
which long-term pharmacologic NOS inhibition improved pro-
teinuria and renal histopathology [55].
Careful experiments are needed to clarify whether inhibition of
NO will have a net beneficial or detrimental effect in glomerulo-
nephritis. The design of such experiments should include attempts
to determine whether NO generation in immunologically injured
glomeruli reaches biologically relevant levels. One should not
underestimate the efficiency with which nitric oxide can be
removed and neutralized immediately after its generation at the
site of inflammatory injury, and the fact that nitric oxide itself is
far less reactive and toxic at biologically relevant concentrations
than in vitro experiments suggest. Most studies in the literature in
general and in the nephrology literature in particular, have not
measured the biologically relevant concentrations of NO in
glomeruli and may have erroneously assumed that NO is being
continuously generated because of its short half-life. However,
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NO is an uncharged molecule that can diffuse through most cells
and tissues with little consumption or direct reaction [56]. A very
efficient removal mechanism of NO is generated at the site of
inflammation and is provided by red blood cells which rapidly
destroy NO following its avid binding to red blood cell oxy-
hemoglobin. Thus, red blood cells can rapidly reduce intracellular
concentrations of NO in NO-producing cells or extracellular
concentrations of NO at a site of inflammatory injury. Glomeruli
are typically hyperemic in glomerulonephritis. Therefore, a quite
efficient removal of NO generated within the glomerular milieu
can be expected. Whether NO concentrations in nephritic glomer-
uli reaches levels sufficient to cause cell injury via formation of
peroxynitrite is unknown. Most studies have measured ex vivo
production of NO in nephritic glomeruli by assessing concentra-
tion of nitrite/nitrate. In these studies, prolonged (up to 48 hr)
incubations are usually required in the presence of the NOS
substrate, L-arginine [12–14]. This approach may not provide an
estimate of the biologically relevant concentrations of NO at-
tained within nephritic glomeruli. For example, NO concentra-
tions of about 5 nM cause vasodilation by activating guanylate
cyclase and can, therefore, be assumed as “homeostatic.” In
contrast, mM concentrations of NO are required to compete with
superoxide dismutase and react with superoxide to generate
peroxynitrite. Are such concentrations of NO achieved in ne-
phritic glomeruli? Newer direct NO detection methods using
chemiluminescence detectors may provide accurate estimates of
“glomerular” NO concentrations.
The demonstration that expression of iNOS is enhanced in
glomerulonephritis raises the obvious question of whether selec-
tive inhibition of this NOS isoform while leaving the constitutive
isoform intact would have a beneficial anti-inflammatory effect.
Increasingly selective iNOS inhibitors are now becoming available
and may serve as powerful tools to definitively address the role of
iNOS-derived NO in the pathobiology of glomerulonephritis.
Such inhibitors have shown promising results in other forms of
inflammation, specifically in adjuvant-induced arthritis in rats and
in carrageenan-induced subcutaneous inflammation. In these
models, it was shown that iNOS inhibition attenuates nitrite
accumulation, leukocyte infiltration and the histopathological
severity of the lesions [57, 58]. Moreover, these beneficial effects
were not associated with systemic hypertension as a result of NO
synthesis inhibition. The efficacy of iNOS inhibition in ameliorat-
ing the extent of glomerular injury and proteinuria in glomerulo-
nephritis is unknown. Selective inhibition of iNOS would still
reduce NO generation thereby promoting renal vasoconstriction,
platelet aggregation and leukocyte adherence to the glomerular
capillary endothelium. This could offset the potential benefit of
selective iNOS inhibition. Indeed, in a rat model of rapidly
progressive crescentic nephritis, iNOS inhibition using a relatively
selective inhibitor worsened proteinuria [65]. Although increas-
ingly selective iNOS inhibitors are being developed, they are not
entirely without an inhibitory effect on constitutive NOS and this
may be sufficient to cause renal vasoconstriction. The recent
development of transgenic mice lacking the iNOS gene [59] may
provide a definitive tool to assess the role of iNOS in the biology
of glomerulonephritis.
Little is known about activation of inducible cyclooxygenase or
nitric oxide synthase in human forms of glomerulonephritis. This
is particularly important insofaras activation of iNOS is concerned
as this form of iNOS may not be induced in human macrophages
infiltrating immunologically injured glomeruli. Indeed, the cir-
cumstances required for the release of iNOS-derived NO in
human macrophages are controversial. That human monocytes/
macrophages contain and can express the iNOS gene is well
established. The accumulation of iNOS mRNA and protein has
been documented in interferon-gamma (IFN-g) and TNF-stimu-
lated human monocytes, and in monocytes cultured with HIV-1
[60, 61]. However, the actual production of NO by human
monocytes/macrophages differs from that of rodent macrophages.
While treatment of rodent macrophages with established iNOS
inductants such as interferon gamma (IFN-g), tumor necrosis
factor (TNF) or lipopolysaccharide (LPS) results in rapid and
abundant accumulation of NO, the amount of NO metabolites
released by human macrophages is modest when compared with
production in rodent cells. Also, induction of iNOS requires a
period of stimulation of several days [62]. This has lead to the
proposal that the human macrophage iNOS is a relatively low-
output system. However, notable exceptions to this slow induc-
tion/slow output system also exist. Human monocytes produce
large amounts of NO2
2 when cultured with M. avium [62].
Unstimulated cultured human peripheral blood monocytes pro-
duce relatively high levels of NO2
2 (26 nmol/106 cells/day) during
the first day of culture and production increases linearly or
abruptly after six days in culture [63]. Finally, cross-linking of the
CD69 cell surface receptor in human monocytes results in rapid
production of NO2
2 [64]. Collectively, these observations point to
limitations of the animal (in particular rodent) models of inflam-
mation in studying activation of the L-arginine:NO system. They
also suggest a more sophisticated and tightly regulated system for
iNOS-derived NO in human as compared to rodent forms of
macrophage-dependent forms of inflammation.
CONCLUDING REMARKS
In glomerulonephritis the arachidonic acid pathway to cy-
clooxygenation and lipoxygenation eicosanoids and the L-arginine
to NO pathway are coactivated. Regulatory interactions between
the two pathways may occur as a result of NO binding to iron
containing centers of cyclooxygenase and lipoxygenases. Evidence
that NO can up-regulate cyclooxygenase activity is firm while
evidence that NO may also regulate activity of lipoxygenases is
emerging. In experimental forms of glomerulonephritis, inducible
isoforms of cyclooxygenase and nitric oxide synthase are ex-
pressed. This may lead to sustained generation of proinflamma-
tory prostaglandins and TxA2, and in high output generation of
NO. Whereas evidence that eicosanoids have a direct cytotoxic
effect is lacking, the cytotoxic effect of NO is well established
particularly when NO reacts with superoxide to form the strong
and relatively stable oxidant peroxynitrite. Whether the concen-
trations of NO or peroxynitrite attained in the glomerular milieu
in the course of glomerulonephritis are sufficient to cause cyto-
toxicity by this mechanism is unknown. Detection of nitrotyrosine-
containing proteins in glomeruli using immunohistochemical
methods may provide a means of assessing the extent of peroxyni-
trite-induced cell injury. Without such demonstration, the argu-
ment that iNOS-derived NO causes cell injury in the course of
glomerulonephritis remains unfounded. Obtaining such evidence
is important in order to justify use of selective iNOS inhibitors to
reduce generation of iNOS-derived NO in glomerulonephritis. A
serious adverse effect of NO inhibition is renal vasoconstriction
with intraglomerular and/or systemic hypertension. Therefore,
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beneficial effects expected as a result of iNOS inhibition should be
carefully weighed against such adverse sequelae. Oxy-hemoglobin
in red blood cells provides a very efficient system of removing NO
following its release. On the other hand, superoxide dismutase
provides an efficient system to remove O2
2. These two systems
prevent reaction of O2
2 with NO to form the potent oxidant
ONOO2. This, and the ability of NO to diffuse through cells and
tissues with little consumption or direct reaction, raises skepticism
and urges carefully conducted studies to confirm the cytotoxic
potential of NO in glomerulonephritis. This is particularly true in
humans because human macrophages infiltrating nephritic glo-
meruli may be unable to up-regulate activity of the inducible
NOS.
Reprint requests to Elias A. Lianos, M.D., Nephrology Division, Depart-
ment of Medicine, Medical College of Wisconsin, 9200 W. Wisconsin Avenue,
Milwaukee, Wisconsin 53226, USA.
APPENDIX
Abbreviations used in this article are: COX, cyclooxygenase; GBM,
glomerular basement membrane; GFR, glomerular filtration rate; HETE,
hydroxyeicosatetraenoic acid; IL, interleukin; INF-g, interferon-gamma;
iNOS, inducible nitric oxide synthase; LPS, lipopolysaccharide; LT, leu-
kotriene; Kf, ultrafiltration coefficient; NO, nitric oxide; NO2
1, nitronium
ion; NOS, nitric oxide synthase; NSAIDs, non-steroidal anti-inflammatory
drugs; O2
2, superoxide; OHz, hydroxyl radical; ONOO2, peroxynitrite;
PG, prostaglandin; PGI2, prostacycline; RBF, renal blood flow; TNF,
tumor necrosis factor; Tx, thromboxane.
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